Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Kempner Capital Management Inc.

Kempner Capital Management Inc. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 46.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 31,401 shares of the medical equipment provider’s stock after selling 27,095 shares during the period. Zimmer Biomet comprises 2.6% of Kempner Capital Management Inc.’s investment portfolio, making the stock its 15th biggest position. Kempner Capital Management Inc.’s holdings in Zimmer Biomet were worth $3,093,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Resona Asset Management Co. Ltd. lifted its holdings in Zimmer Biomet by 5.7% in the second quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider’s stock valued at $6,197,000 after acquiring an additional 3,634 shares during the period. QSM Asset Management Ltd increased its holdings in shares of Zimmer Biomet by 36.1% during the 2nd quarter. QSM Asset Management Ltd now owns 111,500 shares of the medical equipment provider’s stock valued at $10,174,000 after purchasing an additional 29,600 shares in the last quarter. Truist Financial Corp increased its holdings in shares of Zimmer Biomet by 34.4% during the 2nd quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock valued at $2,446,000 after purchasing an additional 6,867 shares in the last quarter. Magellan Asset Management Ltd lifted its stake in shares of Zimmer Biomet by 16.8% in the 2nd quarter. Magellan Asset Management Ltd now owns 505,901 shares of the medical equipment provider’s stock valued at $46,143,000 after purchasing an additional 72,613 shares during the period. Finally, State of Alaska Department of Revenue boosted its holdings in Zimmer Biomet by 89.8% during the second quarter. State of Alaska Department of Revenue now owns 44,261 shares of the medical equipment provider’s stock worth $4,036,000 after buying an additional 20,945 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of recent analyst reports. Barclays cut their price objective on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a report on Wednesday, November 5th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $100.00 price target (down previously from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Stifel Nicolaus set a $110.00 price target on Zimmer Biomet in a research report on Wednesday, November 5th. Citigroup dropped their price objective on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Finally, Royal Bank Of Canada reduced their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $107.50.

Zimmer Biomet Trading Up 0.6%

ZBH stock opened at $90.78 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $85.33 and a 12-month high of $114.44. The business’s 50-day moving average is $94.07 and its 200 day moving average is $96.57. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. The stock has a market cap of $17.99 billion, a price-to-earnings ratio of 22.47, a PEG ratio of 2.37 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.02. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, December 30th. Zimmer Biomet’s payout ratio is 23.76%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.